Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.2144/fsoa-2023-0074 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|